Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common symptoms feared by patients, but may be prevented or lessened with appropriate medications. Several antiemetic options exist to manage CINV. Corticosteroids, serotonin receptor antagonists, and neurokinin receptor antagonists are the classes most commonly used in the prevention of CINV. There are many alternative drug cla...

The Effect of Semi-Upright Position on Incidence and Intensity of Chemotherapy-Induced Nausea and Vomiting

A Prospective Triple-blind Randomized Trial on Safety and Efficacy of Abitant in the Prevention of Chemotherapy-Induced Nausea and Vomiting

Background: Oral Aprepitant, a neurokinin-1 receptor antagonist, is suggested in combination with other antiemetic agents in preventing chemotherapy-induced nausea and vomiting(CINV) associated with emetogenic chemotherapeutic regimens in adolescents, but its efficacy and safety in pediatric patients more than six months are unknown. in this study, we used abitant drug (a generic name of Aprepi...

Randomised, prospective, controlled trial comparing tropisetron with metoclopramide and placebo in controlling postoperative nausea and vomiting.

OBJECTIVE To compare the results of Tropisetron, Metoclopramide and placebo on postoperative nausea and vomiting in patients undergoing minilaparotomy cholecystectomy. SETTING Patients operated for minilaparotomy cholecystectomy in two private hospitals in Karachi. SUBJECTS Fifty consecutive patients of all ages and both sex who had simple cholelithiasis and underwent minilaparotomy cholecy...

Oncology Patient Evidence-Based Notes (OPEN): antiemetics for chemotherapy-induced nausea and vomiting.

Since the 1990s, new antiemetic agents have significantly reduced the incidence of nausea and vomiting associated with chemotherapy. Specifically, these agents are the serotonin receptor antagonists and consist of dolasetron (Anzamet, Aventis Pharmaceuticals, Bridgewater, NJ), granisetron (Kytril, Roche Pharmaceuticals, Nutley, NJ), ondansetron (Zofran, GlaxoSmithKline, Research Triangle Park, ...